Report cover image

Periodontitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Apr 29, 2022
Length 53 Pages
SKU # GMD17181956

Description

Periodontitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Periodontitis - Drugs In Development, 2022, provides an overview of the Periodontitis (Mouth And Dental Disorders) pipeline landscape.

Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, bright red or purplish gums, bad breath, bright red or purplish gums and spaces developing between teeth. Risk factors include gingivitis, heredity, diabetes, age, substance abuse and weakened immune system.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Periodontitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Periodontitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Periodontitis (Mouth And Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 5 and 4 respectively. Similarly, the Universities portfolio in Phase 0, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Periodontitis (Mouth And Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Periodontitis (Mouth And Dental Disorders).
  • The pipeline guide reviews pipeline therapeutics for Periodontitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Periodontitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Periodontitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Periodontitis (Mouth And Dental Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Periodontitis (Mouth And Dental Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Periodontitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

53 Pages
Introduction
Global Markets Direct Report Coverage
Periodontitis – Overview
Periodontitis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Periodontitis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Periodontitis – Companies Involved in Therapeutics Development
Amyndas Pharmaceuticals LLC
Beijing SH biotechnology Co Ltd
Cellatoz Therapeutics Inc
Cells for Cells SA
Chengdu Shiliankangjian Biotechnology Co Ltd
Cytopeutics Pte Ltd
Denteric Pty Ltd
Geistlich Pharma AG
GEXVal Inc
KIMS Pharmaceutical Co Ltd
MetiMedi Pharmaceuticals Co Ltd
Noveome Biotherapeutics Inc
PerioTrap Pharmaceuticals GmbH
Periodontitis – Drug Profiles
AMY-101 – Drug Profile
Cell Therapy for Periodontitis – Drug Profile
CLV-100 – Drug Profile
CLZ-1001 – Drug Profile
Drug to Antagonize C5aR for Periodontitis – Drug Profile
Fusion Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis – Drug Profile
GXV-003 – Drug Profile
KIMS-004 – Drug Profile
METI-101 – Drug Profile
minocycline – Drug Profile
PODOH-CRC – Drug Profile
Ranokure – Drug Profile
Small Molecule to Inhibit Glutaminyl Cyclase for Periodontitis – Drug Profile
ST-266 – Drug Profile
Stem Cell Therapy for Periodontitis – Drug Profile
Synthetic Peptides for Periodontitis – Drug Profile
TAPS-18 – Drug Profile
taurolidine – Drug Profile
Periodontitis – Dormant Projects
Periodontitis – Discontinued Products
Periodontitis – Product Development Milestones
Featured News & Press Releases
Jun 04, 2020: Cellatose announces Korea-US patent registration
Aug 26, 2019: Amyndas Pharmaceuticals initiates phase 2a study of AMY-101 in adults with periodontal inflammation and gingivitis
Dec 13, 2017: Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its new complement C3 inhibitor AMY-101
Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis
Mar 07, 2016: Penn Team Reverses Signs of Naturally Occurring Chronic Periodontitis
May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Periodontitis, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Universities/Institutes, 2022
Table 4: Products under Development by Companies, 2022
Table 5: Products under Development by Universities/Institutes, 2022
Table 6: Number of Products by Stage and Target, 2022
Table 7: Number of Products by Stage and Mechanism of Action, 2022
Table 8: Number of Products by Stage and Route of Administration, 2022
Table 9: Number of Products by Stage and Molecule Type, 2022
Table 10: Periodontitis – Pipeline by Amyndas Pharmaceuticals LLC, 2022
Table 11: Periodontitis – Pipeline by Beijing SH biotechnology Co Ltd, 2022
Table 12: Periodontitis – Pipeline by Cellatoz Therapeutics Inc, 2022
Table 13: Periodontitis – Pipeline by Cells for Cells SA, 2022
Table 14: Periodontitis – Pipeline by Chengdu Shiliankangjian Biotechnology Co Ltd, 2022
Table 15: Periodontitis – Pipeline by Cytopeutics Pte Ltd, 2022
Table 16: Periodontitis – Pipeline by Denteric Pty Ltd, 2022
Table 17: Periodontitis – Pipeline by Geistlich Pharma AG, 2022
Table 18: Periodontitis – Pipeline by GEXVal Inc, 2022
Table 19: Periodontitis – Pipeline by KIMS Pharmaceutical Co Ltd, 2022
Table 20: Periodontitis – Pipeline by MetiMedi Pharmaceuticals Co Ltd, 2022
Table 21: Periodontitis – Pipeline by Noveome Biotherapeutics Inc, 2022
Table 22: Periodontitis – Pipeline by PerioTrap Pharmaceuticals GmbH, 2022
Table 23: Periodontitis – Dormant Projects, 2022
Table 24: Periodontitis – Dormant Projects, 2022 (Contd..1)
Table 25: Periodontitis – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Periodontitis, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Targets, 2022
Figure 5: Number of Products by Stage and Targets, 2022
Figure 6: Number of Products by Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Mechanism of Actions, 2022
Figure 8: Number of Products by Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 10: Number of Products by Molecule Types, 2022
Figure 11: Number of Products by Stage and Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us